Phathom Pharmaceuticals (PHAT) Income Statement & Balance Sheet → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free PHAT Stock Alerts $10.54 -0.15 (-1.40%) (As of 05/17/2024 ET) Add Compare Share Share FinancialsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Phathom Pharmaceuticals Income Statement, Balance Sheet and Cash Flow Statement→ 41 banks launch ‘crypto dollar’ (Ad) Related Companies: IGM Biosciences Financial Statements Calliditas Therapeutics AB (publ) Financial Statements ArriVent BioPharma Financial Statements Stoke Therapeutics Financial Statements Aerovate Therapeutics Financial Statements GH Research Financial Statements Olema Pharmaceuticals Financial Statements Avid Bioservices Financial Statements Zymeworks Financial Statements Pharming Group Financial Statements Receive PHAT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PHAT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyDems have chosen Biden replacement?Paradigm Press41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford Club4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
